Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00293657 · ClinicalTrials.gov registry record · Phase 2
Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.
A Phase 2 study, sponsored by POZEN.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00293657 is a Phase 2 study that has completed, run by POZEN. The registered enrollment target is 150 participants.
The verdict
NCT00293657, a Phase 2 study, has completed, sponsored by POZEN.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
To determine whether a single dose of intravenous lornoxicam is superior to intravenous placebo for the acute treatment of moderate or severe headache associated with a single migraine attack in patients with a history of migraine. Two-thirds of patients in this study will receive a single dose of intravenous lornoxicam (8mg or 16 mg) and one-third of patients will receive a single dose of an intravenous placebo.
Interventions
- DRUG Placebo
- DRUG Lornoxicam 8 mg
- DRUG Lornoxicam 16 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2005-12 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00293657
The ClinicalTrials.gov registry entry for NCT00293657 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is POZEN, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00293657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00293657 about?
NCT00293657 is a clinical study titled "Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.". To determine whether a single dose of intravenous lornoxicam is superior to intravenous placebo for the acute treatment of moderate or severe headache associated with a single migraine attack in patients with a history of migraine. Two-thirds of patients in this study will receive a single dose of i...
What is the current status of trial NCT00293657?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2005-12. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00293657?
The interventions under investigation include: Placebo (DRUG), Lornoxicam 8 mg (DRUG), Lornoxicam 16 mg (DRUG).
Who is sponsoring clinical trial NCT00293657?
This trial is sponsored by POZEN, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.